



P: 734-429-9053 | F: 734-944-3934

968 E Michigan Ave | Saline, MI 48176

Mon - Fri: 9am-6pm | Sat: 9am-3pm | Sun: Closed

ELECTRONIC PRESCRIBING (E-PRESCRIBING)

Compounded Semaglutide 1mg-1ml in SubMagna™ HMW

1. Identify *Jensen's Community Pharmacy - Saline* as the Desired Pharmacy in EMR System
 - Phone Number: 734-429-9053
 - Address: 968 E Michigan Ave, Saline, MI 48176
 - NPI: 1093084303
2. Select the medication – Two Options Typically Considered
 - If your EMR system allows you to free-form a compounded medication that does not have a single-number NDC, consider free-form typing "Compounded Semaglutide 1mg-1ml in SubMagna™ HMW" as the prescribed medication.
 - If your EMR system does NOT allow you to free-form a compounded medication, consider selecting RYBELSUS® 14mg Tablet and adding the clarification for the specific medication prescribed in the SIG or Prescription Direction Field as described below in #3.
3. Add the Directions or "SIG" (Use to Embed Compound Name and Compound Directions – Pick One)
 - Option 1 for GLP-1 naive patients: Write into notes: "Compounded Semaglutide Sublingual 13-Week Protocol." This includes the following:
 - Weeks 1-5: Semaglutide 2mg/ml: 0.5ml (1mg) daily for 2 weeks and increase to 1ml (2mg) daily
 - Assess efficacy for patient and increase if needed
 - Weeks 6-9: Semaglutide 3mg/ml: take 1ml (3mg) daily
 - Assess efficacy for patient and increase if needed
 - Weeks 10-13: Semaglutide 4mg/ml: take 1ml (4mg) daily
 - Assess efficacy for patient and increase if needed
 - Option 2 for patients who have been on a GLP-1 recently: Compounded Semaglutide 1mg-1ml in SubMagna™
 - Patients will need a higher dose to start than GLP-1 naive patients. Recommended starting dose is 3mg daily.
 - HMW – Once daily, place ____ml under tongue for a minimum of 2 minutes before swallowing. Do not eat or drink for 30 minutes after taking.
4. Select Quantity in 30ml increments
5. Enter Number of Authorized Refills

Above is general proposed guidance that should be adapted to each individual prescriber's practice setting. No compounded medication is reviewed by FDA for safety or efficacy. RYBELSUS® is a registered trademark of Novo Nordisk A/S. SubMagna™ HMW is a trademark of Kingdom Licensing.

Questions? Contact us! 734-429-9053